Second and higher-order malignancies now comprise about 18% of all incident cancers in the USA, superseding first primary cancers of the breast, lung, and prostate. The occurrence of second malignant neoplasms (SMN) is influenced by a myriad of factors, including the late effects of cancer therapy, shared aetiological factors with the primary cancer (such as tobacco use, excessive alcohol intake, and obesity), genetic predisposition, environmental determinants, host effects, and combinations of factors, including gene–environment interactions. The influence of these factors on SMN in survivors of adult-onset cancer is reviewed here. We also discuss how modifiable behavioural and lifestyle factors may contribute to SMN, and how these factors can be managed. Cancer survivorship provides an opportune time for oncologists and other health-care providers to counsel patients with regard to health promotion, not only to reduce SMN risk, but to minimize co-morbidities. In particular, the importance of smoking cessation, weight control, physical activity, and other factors consonant with adoption of a healthy lifestyle should be consistently emphasized to cancer survivors. Clinicians can also play a critical role by endorsing genetic counselling for selected patients and making referrals to dieticians, exercise trainers, and others to assist with lifestyle change interventions.
Second and higher-order malignancies now comprise about 18% of all incident cancers in the USA
Second malignant neoplasms (SMN) reflect the role of many factors, including the late effects of therapy, shared aetiological factors, genetic predisposition, environmental determinants, host effects, and combinations of influences
Cancer survivorship provides an opportune time for oncologists and other healthcare providers to counsel patients with regard to health promotion to reduce SMN risk
The importance of smoking cessation, weight control, physical activity, and other factors consonant with adoption of a healthy lifestyle should be consistently emphasized to cancer survivors
Clinicians can play a critical role by endorsing genetic counselling for selected patients and making referrals to dieticians, exercise trainers, and others to assist with lifestyle change interventions
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
National Cancer Institute. SEER Cancer Statistics Review, 1975–2007 [online], (2010).
National Cancer Institute. Provocative questions: identifying problems to drive progress against cancer [online], (2012).
Siegel, R. et al. Cancer treatment and survivorship statistics. CA Cancer J. Clin. 62, 220–241 (2012).
[No authors listed]. Cancer survivors: living longer, and now, better. Lancet 364, 2153–2154 (2004).
Travis, L. B. Therapy-associated solid tumors. Acta Oncol. 41, 323–333 (2002).
Curtis, R. E., Ron, E., Hankey, B. F. & Hoover, R. N. in New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973–2000 (eds Curtis, R. E. et al.) NIH Publ. No. 05–0532, 181–206 (National Cancer Institute, 2006).
Ng, A. K. et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J. Clin. Oncol. 20, 2101–2108 (2002).
Travis, L. B. et al. Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J. Natl Cancer Inst. 98, 15–25 (2006).
Travis, L. B., Bhatia, S., Allan, J. M., Oeffinger, K. C. & Ng, A. in Cancer: Principles and Practice of Oncology, 9th edn (eds Devita, V. T., Lawrence, T. S. & Rosenberg, S. A.) 2393–2410 (Lippincott Williams and Wilkins, 2011).
Dores, G. M. et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J. Clin. Oncol. 20, 3484–3494 (2002).
Franklin, J. et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann. Oncol. 17, 1749–1760 (2006).
Omer, B. et al. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. Br. J. Haematol. 158, 615–625 (2012).
Hodgson, D. C. et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J. Clin. Oncol. 25, 1489–1497 (2007).
Hemminki, K., Liu, H. & Sundquist, J. Second cancers after testicular cancer diagnosed after in Sweden. Ann. Oncol. 21, 1546–1551 (2010) (1980).
Travis, L. B. et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J. Natl Cancer Inst. 97, 1354–1365 (2005).
van den Belt-Dusebout, A. W. et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol. 25, 4370–4378 (2007).
Travis, L. B. et al. Second malignant neoplasms and cardiovascular disease following radiotherapy. J. Natl Cancer Inst. 104, 357–370 (2012).
National Council on Radiation Protection and Measurements. Report No. 170: Second Primary Cancers and Cardiovascular Disease After Radiotherapy [online], (2012).
Chaturvedi, A. K. et al. Second cancers among 104, 760 survivors of cervical cancer: evaluation of long-term risk. J. Natl Cancer Inst. 99, 1634–1643 (2007).
Bhojani, N. et al. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int. J. Radiat. Oncol. Biol. Phys. 76, 342–348 (2010).
Rapiti, E. et al. Increased risk of colon cancer after external radiation therapy for prostate cancer. Int. J. Cancer 123, 1141–1145 (2008).
Kirova, Y. M., Vilcoq, J. R., Asselain, B., Sastre-Garau, X. & Fourquet, A. Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. Cancer 104, 856–863 (2005).
Nakamura, R. et al. Angiosarcoma arising in the breast following breast-conserving surgery with radiation for breast carcinoma. Breast Cancer 14, 245–249 (2007).
Rubino, C. et al. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res. Treat. 89, 277–288 (2005).
Kaufman, E. L., Jacobson, J. S., Hershman, D. L., Desai, M. & Neugut, A. I. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J. Clin. Oncol. 26, 392–398 (2008).
Neugut, A. I. et al. Lung cancer after radiation therapy for breast cancer. Cancer 71, 3054–3057 (1993).
Zablotska, L. B., Chak, A., Das, A. & Neugut, A. I. Increased risk of squamous cell esophageal cancer after adjuvant radiation therapy for primary breast cancer. Am. J. Epidemiol. 161, 330–337 (2005).
Boice, J. D. Jr, Harvey, E. B., Blettner, M., Stovall, M. & Flannery, J. T. Cancer in the contralateral breast after radiotherapy for breast cancer. N. Engl. J. Med. 326, 781–785 (1992).
Hooning, M. J. et al. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J. Clin. Oncol. 26, 5561–5568 (2008).
Stovall, M. et al. Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study. Int. J. Radiat. Oncol. Biol. Phys. 72, 1021–1030 (2008).
Berrington de Gonzalez, A. et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 12, 353–360 (2011).
Engert, A. et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N. Engl. J. Med. 363, 640–652 (2010).
Girinsky, T. et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother. Oncol. 79, 270–277 (2006).
Harris, J. R. & Hellman, S. Put the “hockey stick” on ice. Int. J. Radiat. Oncol. Biol. Phys. 15, 497–499 (1988).
Classen, J. et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J. Clin. Oncol. 21, 1101–1106 (2003).
Classen, J. et al. Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). Br. J. Cancer 90, 2305–2311 (2004).
Wong, F. L. et al. Cancer incidence after retinoblastoma. radiation dose and sarcoma risk. JAMA 278, 1262–1267 (1997).
Kuttesch, J. F. Jr et al. Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J. Clin. Oncol. 14, 2818–2825 (1996).
Travis, L. B. et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290, 465–475 (2003).
Travis, L. B. et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J. Natl Cancer Inst. 94, 182–192 (2002).
van den Belt-Dusebout, A. W. et al. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int. J. Radiat. Oncol. Biol. Phys. 75, 1420–1429 (2009).
Neglia, J. P. et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J. Natl Cancer Inst. 98, 1528–1537 (2006).
Bhatti, P. et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the Childhood Cancer Survivor Study. Radiat. Res. 174, 741–752 (2010).
Sigurdson, A. J. et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet 365, 2014–2023 (2005).
De Bruin, M. L. et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J. Clin. Oncol. 27, 4239–4246 (2009).
Ng, A. K. et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 100, 1989–1996 (2002).
Kry, S. F. et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 62, 1195–1203 (2005).
Purdy, J. A. Dose to normal tissues outside the radiation therapy patient's treated volume: a review of different radiation therapy techniques. Health Phys. 95, 666–676 (2008).
Brodin, N. P. et al. Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. Acta Oncol. 50, 806–816 (2011).
Bednarz, B., Athar, B. & Xu, X. G. A comparative study on the risk of second primary cancers in out-of-field organs associated with radiotherapy of localized prostate carcinoma using Monte Carlo-based accelerator and patient models. Medical Phys. 37, 1987–1994 (2010).
Zwahlen, D. R. et al. Effect of intensity-modulated pelvic radiotherapy on second cancer risk in the postoperative treatment of endometrial and cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 74, 539–545 (2009).
Zacharatou Jarlskog, C. & Paganetti, H. Risk of developing second cancer from neutron dose in proton therapy as function of field characteristics, organ, and patient age. Int. J. Radiat. Oncol. Biol. Phys. 72, 228–235 (2008).
Swerdlow, S. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn (IARC Press, 2008).
Sill, H., Olipitz, W., Zebisch, A., Schulz, E. & Wolfler, A. Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. Br. J. Pharmacol. 162, 792–805 (2011).
Attal, M. et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366, 1782–1791 (2012).
McCarthy, P. L. et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366, 1770–1781 (2012).
Pedersen-Bjergaard, J., Pedersen, M., Roulston, D. & Philip, P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 86, 3542–3552 (1995).
Leone, G., Pagano, L., Ben-Yehuda, D. & Voso, M. T. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 92, 1389–1398 (2007).
Travis, L. B. et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N. Engl. J. Med. 340, 351–357 (1999).
Travis, L. B. et al. Treatment-associated leukemia following testicular cancer. J. Natl Cancer Inst. 92, 1165–1171 (2000).
Pedersen-Bjergaard, J. et al. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 338, 359–363 (1991).
Seedhouse, C. & Russell, N. Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia. Br. J. Haematol. 137, 513–529 (2007).
Godley, L. A. & Larson, R. A. Therapy-related myeloid leukemia. Semin. Oncol. 35, 418–429 (2008).
Leleu, X. et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J. Clin. Oncol. 27, 250–255 (2009).
Morrison, V. A. et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an Intergroup Study, Cancer and Leukemia Group B 9011. J. Clin. Oncol. 20, 3878–3884 (2002).
Neugut, A. I., Robinson, E., Nieves, J., Murray, T. & Tsai, W. Y. Poor survival of treatment-related acute nonlymphocytic leukemia. JAMA 264, 1006–1008 (1990).
Mauritzson, N. et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001. Leukemia 16, 2366–2378 (2002).
Schoch, C., Kern, W., Schnittger, S., Hiddemann, W. & Haferlach, T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 18, 120–125 (2004).
Lyman, G. H. & Dale, D. C. Long-term outcomes of myeloid growth factor treatment. J. Natl Compr. Canc. Netw. 9, 945–952 (2011).
Hershman, D. et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J. Natl Cancer Inst. 99, 196–205 (2007).
Lyman, G. H. et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J. Clin. Oncol. 28, 2914–2924 (2010).
Henderson, T. O. et al. Risk factors associated with secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study. Int. J. Radiat. Oncol. Biol. Phys. 84, 224–230 (2012).
Swerdlow, A. J. et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J. Clin. Oncol. 19, 1610–1618 (2001).
van Leeuwen, F. E. et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J. Natl Cancer Inst. 87, 1530–1537 (1995).
Swerdlow, A. J. et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J. Clin. Oncol. 29, 4096–4104 (2011).
Andre, M. et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood 103, 1222–1228 (2004).
Mudie, N. Y. et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British cohort study. J. Clin. Oncol. 24, 1568–1574 (2006).
Nottage, K. et al. Secondary colorectal carcinoma after childhood cancer. J. Clin. Oncol. 30, 2552–2558 (2012).
Henderson, T. O. et al. Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. Ann. Intern. Med. 156, 757–766 (2012).
Travis, L. B. et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J. Natl Cancer Inst. 87, 524–530 (1995).
Bermejo, J. L., Sundquist, J. & Hemminki, K. Bladder cancer in cancer patients: population-based estimates from a large Swedish study. Br. J. Cancer 101, 1091–1099 (2009).
Veiga, L. H. et al. Chemotherapy and thyroid cancer risk: a report from the childhood cancer survivor study. Cancer Epidemiol. Biomarkers Prev. 21, 92–101 (2012).
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771–784 (2011).
Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90, 1371–1388 (1998).
Cuzick, J. et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 11, 1135–1141 (2010).
Burstein, H. J. et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol. 28, 3784–3796 (2010).
Witherspoon, R. P. et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N. Engl. J. Med. 321, 784–789 (1989).
Milligan, D. W. et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br. J. Haematol. 106, 1020–1026 (1999).
Brown, J. R. et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J. Clin. Oncol. 23, 2208–2214 (2005).
Bhatia, S. et al. Malignant neoplasms following bone marrow transplantation. Blood 87, 3633–3639 (1996).
Rizzo, J. D. et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113, 1175–1183 (2009).
Curtis, R. E. et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94, 2208–2216 (1999).
Curtis, R. E. et al. Solid cancers after bone marrow transplantation. N. Engl. J. Med. 336, 897–904 (1997).
Krishnan, A. et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 95, 1588–1593 (2000).
Socie, G., Baker, K. S. & Bhatia, S. Subsequent malignant neoplasms after hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 18 (Suppl.), S139–S150 (2012).
Landgren, O. et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 113, 4992–5001 (2009).
Jagadeesh, D., Woda, B. A., Draper, J. & Evens, A. M. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr. Treat. Options Oncol. 13, 122–136 (2012).
Friedman, D. L. et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood 111, 939–944 (2008).
Bhatia, S. et al. Solid cancers after bone marrow transplantation. J. Clin. Oncol. 19, 464–471 (2001).
Gallagher, G. & Forrest, D. L. Second solid cancers after allogeneic hematopoietic stem cell transplantation. Cancer 109, 84–92 (2007).
Majhail, N. S. et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 117, 316–322 (2011).
Leisenring, W., Friedman, D. L., Flowers, M. E., Schwartz, J. L. & Deeg, H. J. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J. Clin. Oncol. 24, 1119–1126 (2006).
King, M. C., Marks, J. H., Mandell, J. B. & New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302, 643–646 (2003).
Stoffel, E. et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 137, 1621–1627 (2009).
Bonadona, V. et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305, 2304–2310 (2011).
Metcalfe, K. A. et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol. Oncol. 96, 222–226 (2005).
Levi, F., Te, V. C., Randimbison, L. & La Vecchia, C. Cancer risk in women with previous breast cancer. Ann. Oncol. 14, 71–73 (2003).
Rhiem, K. et al. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res. 14, R156 (2012).
Reiner, A. S. et al. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the women's environmental cancer and radiation epidemiology study. J. Clin. Oncol. 31, 433–439 (2013).
Domchek, S. M. et al. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer http://dx.doi.org/10.1002/cncr.27842.
Win, A. K. et al. Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome. J. Natl Cancer Inst. 104, 1363–1372 (2012).
Parry, S. et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 60, 950–957 (2011).
Kastan, M. B. DNA damage responses: mechanisms and roles in human disease: 2007 G. H. A. Clowes Memorial Award Lecture. Mol. Cancer Res. 6, 517–524 (2008).
Nutting, C. et al. A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy? Clin. Oncol. (R. Coll. Radiol) 12, 300–304 (2000).
Limacher, J. M., Frebourg, T., Natarajan-Ame, S. & Bergerat, J. P. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int. J. Cancer 96, 238–242 (2001).
Birch, J. M. et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20, 4621–4628 (2001).
Talwalkar, S. S. et al. Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome. Arch. Pathol. Lab. Med. 134, 1010–1015 (2010).
Link, D. C. et al. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA 305, 1568–1576 (2011).
Kleinerman, R. A. et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J. Clin. Oncol. 23, 2272–2279 (2005).
Draper, G. J., Sanders, B. M. & Kingston, J. E. Second primary neoplasms in patients with retinoblastoma. Br. J. Cancer 53, 661–671 (1986).
Sharif, S. et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J. Clin. Oncol. 24, 2570–2575 (2006).
Evans, D. G., Farndon, P. A., Burnell, L. D., Gattamaneni, H. R. & Birch, J. M. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br. J. Cancer 64, 959–961 (1991).
Goldstein, A. M., Yuen, J. & Tucker, M. A. Second cancers after medulloblastoma: population-based results from the United States and Sweden. Cancer Causes Control 8, 865–871 (1997).
Breslow, N. E. et al. Secondary malignant neoplasms after Wilms tumor: an international collaborative study. Int. J. Cancer 127, 657–666 (2010).
Bernstein, J. L. et al. Radiation exposure, the ATM gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. J. Natl Cancer Inst. 102, 475–483 (2010).
Kleinerman, R. A. Radiation-sensitive genetically susceptible pediatric sub-populations. Pediatr. Radiol. 39 (Suppl. 1), S27–S31 (2009).
Allan, J. M. Genetic susceptibility to radiogenic cancer in humans. Health Phys. 95, 677–686 (2008).
Pharoah, P. D. et al. Polygenic susceptibility to breast cancer and implications for prevention. Nat. Genet. 31, 33–36 (2002).
Peto, J. Breast cancer susceptibility-a new look at an old model. Cancer Cell 1, 411–412 (2002).
Berwick, M. et al. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol. Biomarkers Prev. 15, 1520–1525 (2006).
Berwick, M. et al. Interaction of CDKN2A and sun exposure in the etiology of melanoma in the general population. J. Invest. Dermatol. 131, 2500–2503 (2011).
Bishop, D. T. et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J. Natl Cancer Inst. 9, 894–903 (2002).
Di Bernardo, M. C. et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat. Genet. 40, 1204–1210 (2008).
Broderick, P. et al. IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma. Br. J. Haematol. 148, 413–415 (2010).
Duffy, D. L. et al. IRF4 variants have age-specific effects on nevus count and predispose to melanoma. Am. J. Hum. Genet. 87, 6–16 (2010).
Li, S. et al. GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers. PLoS Genet. 8, e1002791 (2012).
de Martel, C. et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 13, 607–615 (2012).
Wood, M. E. et al. Second malignant neoplasms: assessment and strategies for risk reduction. J. Clin. Oncol. 30, 3734–3745 (2012).
Bhatia, S. Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors. Cancer Epidemiol. Biomarkers Prev. 20, 2048–2067 (2011).
Allan, J. M. et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 104, 3872–3877 (2004).
Hernandez-Boluda, J. C. et al. A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera. Blood 119, 5221–5228 (2012).
Best, T. et al. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat. Med. 17, 941–943 (2011).
Castigliano, S. G. Influence of continued smoking on the incidence of second primary cancers involving mouth, pharynx, and larynx. J. Am. Dent. Assoc. 77, 580–585 (1968).
Parsons, A., Daley, A., Begh, R. & Aveyard, P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 340, b5569 (2010).
Lin, K. et al. Second primary malignancy of the aerodigestive tract in patients treated for cancer of the oral cavity and larynx. Head Neck 27, 1042–1048 (2005).
Do, K. A. et al. Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control 14, 131–138 (2003).
Gillison, M. L. et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J. Clin. Oncol. 30, 2102–2111 (2012).
Leon, X. et al. Influence of the persistence of tobacco and alcohol use in the appearance of second neoplasm in patients with a head and neck cancer. A case-control study. Cancer Causes Control 20, 645–652 (2009).
Knight, J. A. et al. Alcohol intake and cigarette smoking and risk of a contralateral breast cancer: the women's environmental cancer and radiation epidemiology study. Am. J. Epidemiol. 169, 962–968 (2009).
Li, C. I., Daling, J. R., Porter, P. L., Tang, M. T. & Malone, K. E. Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. J. Clin. Oncol. 27, 5312–5318 (2009).
Trentham-Dietz, A., Newcomb, P. A., Nichols, H. B. & Hampton, J. M. Breast cancer risk factors and second primary malignancies among women with breast cancer. Breast Cancer Res. Treat. 105, 195–207 (2007).
Levi, F., Randimbison, L., La Vecchia, C., Erler, G. & Te, V. C. Incidence of invasive cancers following squamous cell skin cancer. Am. J. Epidemiol. 146, 734–739 (1997).
Titus-Ernstoff, L. et al. Multiple primary melanoma: two-year results from a population-based study. Arch. Dermatol. 142, 433–438 (2006).
Rigel, D. S., Friedman, R. J. & Kopf, A. W. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J. Am. Acad. Dermatol. 34, 839–847 (1996).
Majed, B., Dozol, A., Ribassin-Majed. L., Senouci, K. & Asselain, B. Increased risk of contralateral breast cancers among overweight and obese women: a time-dependent association. Breast Cancer Res. Treat. 126, 729–738 (2011).
Sanchez, L. et al. Risk factors for second primary tumours in breast cancer survivors. Eur. J. Cancer Prev. 17, 406–413 (2008).
Rock, C. L. et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J. Clin. 62, 243–274 (2012).
Mayne, S. T. et al. Randomized trial of supplemental beta-carotene to prevent second head and neck cancer. Cancer Res. 61, 1457–1463 (2001).
Bairati, I. et al. Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients. Int. J. Cancer 119, 2221–2224 (2006).
World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective [online], (2007).
Smith, R. A. et al. Cancer screening in the United States, a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J. Clin. 61, 8–30 (2011).
Hewitt, M. & Ganz, P. A. (Eds) From Cancer Patient to Cancer Survivor, Lost in Transition: An American Society of Clinical Oncology and Institute of Medicine Symposium (The National Academies Press, 2006).
Saslow, D. et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J. Clin. 57, 75–89 (2007).
Warner, E. et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J. Clin. Oncol. 29, 1664–1669 (2011).
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687–1717 (2005).
Howell, A. et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60–62 (2005).
Coates, A. S. et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98 J. Clin. Oncol. 25, 486–492 (2007).
BIG 1–98 Collaborative Group. et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N. Engl. J. Med. 361, 766–776 (2009).
Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9, 45–53 (2008).
Cuzick, J. et al. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J. Natl Cancer Inst. 99, 272–282 (2007).
Goss, P. E. et al. Exemestane for breast-cancer prevention in postmenopausal women. N. Engl. J. Med. 364, 2381–2391 (2011).
Fisher, B. et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst. 97, 1652–1662 (2005).
Vogel, V. G. et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295, 2727–2741 (2006).
Cuzick, J. et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 12, 496–503 (2011).
Pierce, J. P. et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 298, 289–298 (2007).
Chlebowski, R. T. et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J. Natl Cancer Inst. 98, 1767–1776 (2006).
Friedenreich, C. M., Neilson, H. K. & Lynch, B. M. State of the epidemiological evidence on physical activity and cancer prevention. Eur. J. Cancer 46, 2593–2604 (2010).
Moyer, V. A. & U.S. Preventive Services Task Force. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann. Intern. Med. 18, 900–904 (2012).
Burke, W. et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 277, 915–919 (1997).
Burke, W. et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277, 997–1003 (1997).
Lindor, N. M. et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296, 1507–1517 (2006).
Rosenthal, A. & Jacobs, I. Familial ovarian cancer screening. Best Pract. Res. Clin. Obstet. Gynaecol. 20, 321–338 (2006).
Collaborative Group on Epidemiological Studies of Ovarian Cancer et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371, 303–314 (2008).
Grimbizis, G. F. & Tarlatzis, B. C. The use of hormonal contraception and its protective role against endometrial and ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 24, 29–38 (2010).
Hannaford, P. C. et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 335, 651 (2007).
Hampel, H., Sweet, K., Westman, J. A., Offit, K. & Eng, C. Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J. Med. Genet. 41, 81–91 (2004).
Thiis-Evensen, E. et al. Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study, I. Scand. J. Gastroenterol. 34, 414–420 (1999).
Rothwell, P. M. et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376, 1741–1750 (2010).
Chan, A. T. et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev. Res. (Phila) 5, 164–178 (2012).
Mauch, P. et al. Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9–16, Bellagio, Italy. Eur. J. Haematol. Suppl. 66, 68–76 (2005).
Aberle, D. R. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395–409 (2011).
Liede, A., Karlan, B. Y. & Narod, S. A. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J. Clin. Oncol. 22, 735–742 (2004).
Wolf, A. M. et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J. Clin. 60, 70–98 (2010).
Bishop, J. N., Harland, M., Randerson-Moor, J. & Bishop, D. T. Management of familial melanoma. Lancet Oncol. 8, 46–54 (2007).
Berwick, M., Begg, C. B., Fine, J. A., Roush, G. C. & Barnhill, R. L. Screening for cutaneous melanoma by skin self-examination. J. Natl Cancer Inst. 88, 17–23 (1996).
Travis, L. B. Outcomes in cancer survivors who develop second malignant neoplasms. J. Clin. Oncol. Podcast Archive [online], (2013).
Elena, J. W. et al. Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J. Natl Cancer Inst. 105, 85–94 (2013).
Wheeler, H. E., Maitland, M. L., Dolan, M. E., Cox, N. J. & Ratain, M. J. Cancer pharmacogenomics: strategies and challenges. Nat. Rev. Genet. 14, 23–34 (2013).
Freedman, A. N. et al. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J. Natl Cancer Inst. 102, 1698–1705 (2010).
National Institutes of Health, National Cancer Institute, and the LIVESTRONG Young Adult Alliance. Closing the gap: research and cancer care imperatives for adolescents and young adults with cancer [online], (2006).
Travis, L. B. et al. Testicular cancer survivorship: research strategies and recommendations. J. Natl Cancer Inst. 102, 1114–1130 (2010).
Choi, G. et al. Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms. Cancer Res. 72, 6425–6434 (2012).
Freedman, A. N. et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J. Natl Cancer Inst. 97, 715–723 (2005).
National Childhood Cancer Foundation. Cure Search for Children's Cancer [online], (2013).
Landier, W. et al. Yield of screening for long-term complications using the children's oncology group long-term follow-up guidelines. J. Clin. Oncol. 30, 4401–4408 (2012).
Armstrong, G. T. et al. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J. Clin. Oncol. 29, 3056–3064 (2011).
Milano, M. T., Li, H., Gail, M. H., Constine, L. S. & Travis, L. B. Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based study. J. Clin. Oncol. 28, 5088–5096 (2010).
We thank Ms Laura Finger (Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY) for expert editorial assistance.
The authors declare no competing financial interests.
About this article
Cite this article
Travis, L., Wahnefried, W., Allan, J. et al. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 10, 289–301 (2013). https://doi.org/10.1038/nrclinonc.2013.41
Risk of developing second malignant neoplasms in patients with neuroblastoma: a population study of the US SEER database
Radiation Oncology (2021)
BMC Urology (2021)
Clinical characteristics and overall survival nomogram of second primary malignancies after prostate cancer, a SEER population-based study
Scientific Reports (2021)
Journal of Cancer Survivorship (2020)
Translating research into practice: outcomes from the Healthy Living after Cancer partnership project
BMC Cancer (2020)